US Trends in Type 2 Diabetes Treatment, 1997-2012: Medication Classes

Click here for the NDEI.org Slide Library.
Click here to return to NDEI.org.

  • An analysis examined trends in type 2 diabetes treatment among office-based physicians in the United States from 1997 to 2012.
  • Between 1997 and 2007, there was a steady increase in type 2 diabetes treatment visits, peaking at 35.3 million visits in 2007, and declining to 31.2 million visits in 2012.
  • Diabetes treatments, by medication class:
    • Sulfonylureas: more than half of all visits in 1997 (61%) with continuous decline since; 22% of visits in 2012 
    • Glitazones: increase from 1997 to 2005; 6% of visits in 1997; peak: 41% in 2005; 16% of visits in 2012 (~96% of visits involved pioglitazone products)
    • Biguanide (metformin): Steady increase; 24% of visits in 1997; 53% of visits in 2012
    • DPP-4 inhibitors: 21% of visits since FDA approved in 2006
    • GLP-1 agonists: 4% of visits since FDA approved in 2010
  • Data were from the IMS Health National Disease and Therapeutic Index and the IMS Health National Prescription Audit. Persons aged ≥35 years with a “treatment visit” at which one or more antihyperglycemic agents was used for treatment of type 2 diabetes were included in the analysis. Each product dispensed equates to a separate treatment visit.

Percentages shown are % of treatment visits where medication classes were prescribed  

Turner LW, Nartey D, Stafford RS, Singh S, Alexander GC. Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012. Diabetes Care. 2014;37:985-992.

Any pharmacologic agents discussed are approved for use in the United States by the U.S. Food and Drug Administration (FDA) unless otherwise noted. Consult individual prescribing information for approved uses outside of the United States.

May 2014  

This slide was created by KnowledgePoint360 Group, LLC, and was not associated with funding via an educational grant or a promotional/commercial interest.